Table 5.
Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 15 mg/dL and propensity score-matched patients on placebo
|
All (N = 3128) |
Alirocumab (N = 782) |
Placebo (N = 2346) |
|
|---|---|---|---|
| LDL-C, mmol/L | 2.0 ± 0.5 | 2.0 ± 0.6 | 2.0 ± 0.5 |
| Non-HDL-C, mmol/L | 2.8 ± 0.7 | 2.8 ± 0.7 | 2.8 ± 0.6 |
| Total cholesterol, mmol/L | 3.9 ± 0.7 | 3.9 ± 0.8 | 3.9 ± 0.7 |
| HDL-C, mmol/L | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 |
| Fasting triglycerides, mmol/L | 1.8 ± 1.1 | 1.8 ± 0.9 | 1.8 ± 1.1 |
| Lipoprotein(a), mg/dL | 18.8 ± 23.1 | 19.3 ± 22.4 | 18.7 ± 23.3 |
| Apolipoprotein B, mg/dL | 75.4 ± 16.0 | 76.0 ± 17.5 | 75.2 ± 15.4 |
| Apolipoprotein A1, mg/dL | 129.9 ± 22.9 | 129.2 ± 22.3 | 130.1 ± 23.1 |
| Apolipoprotein B/Apolipoprotein A1 ratioa | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 |
| Total cholesterol/HDL-C ratioa | 3.7 ± 1.0 | 3.7 ± 0.9 | 3.7 ± 1.0 |
Data are presented as mean ± SD
HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, Q Quartile, SD Standard deviation
a Ratios were only calculated if the 2 samples were collected at the same visit